HIV patients to keep receiving promising treatments in new study
NCT ID NCT07393659
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study offers continued access to HIV medications (fostemsavir or dolutegravir/lamivudine) for 183 people who completed earlier ViiV Healthcare studies and are still benefiting. The goal is to provide treatment while collecting more safety information. Participants must have a doctor confirm they still need the treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fostemsavir and Dolutegravir/Lamivudine combination
What this could lead to
If successful, this study helps ensure uninterrupted access to effective HIV treatment for people who need it.
What could go wrong
This is an open-label study without a placebo, so results may be less reliable. It only includes people already benefiting, which may not reflect broader outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••